Dataset from A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00008416
下载链接
链接失效反馈官方服务：
资源简介：
The objective of this study was to evaluate efficacy and safety of regorafenib in patients
with advanced liver cancer who had progressed after sorafenib treatment. Patients were
treated with regorafenib or placebo using a 2:1 randomization scheme.
创建时间：
2025-09-02
